Evommune shares plunge after eczema drug EVO756 fails mid-stage goals
Evommune (EVMN) shares fell more than 15% in extended trading after it said lead candidate EVO756 failed to meet main goals in a mid-stage eczema trial, citing topline data.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.